Dr. Bianchini describes the 🐘 in the room at #SABCS24.

❓Are PD-L1 and PD1 not created equal in breast?

🔑It is clear, neoadjuvant compared to adj immunotherapy should be given

⚠️ highlights ER low should be included in ICI trials

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social

📌 Association Between Risk-Reducing Surgeries and Survival in Young BRCA Carriers with Breast Cancer: Results from an International Cohort Study presented by prof Matteo Lambertini 👏🏻
#SABCS24 #GeneralSession1 #day2 @oncoalert.bsky.social #OncoAlertAF

Does remote symptom monitoring improve fatigue in MBC?

Maybe so. Likely prompts intervention and addressing symptoms sooner than waiting for next visits or having discussion skipped for other priorities in the exam room.

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
#bcsm

Polygenic Risk Score (CRS) in Breast Cancer Risk Assessment

CRS predicted a different risk level than Tyrer-Cuzick (TC) for a substantial proportion of patients

CRS+ &/or TC+ received high-risk screening c/w guidelines for TC+ (recommendations for CRS+ do not exist) #SABCS24

📌 Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial
nature.com/articles/s4146…
@oncoalert.bsky.social#OncoAlertAFAF

www.novartis.com/news/media-r...

www.sciencedirect.com/science/arti...

The results of the SONIA trial on the early vs deferred use of CDK4/6i in advanced breast cancer are now published in @Nature

No statistically significant benefit for the use of CDK4/6i as a first-line compared with second-line treatment

@oncoalert.bsky.social

www.nature.com/articles/s41...

Full trial report here - www.thelancet.com/journals/lan...

Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO trial)

#OncSky #MedSky